MapLight Therapeutics announced its Q4 and full-year 2025 financial results, highlighting a strong cash position of $453.1 million to fund operations through 2027. The company expects to complete enrollment for its Phase 2 ZEPHYR trial for schizophrenia in April 2026 and report topline results for this and its Phase 2 IRIS trial for autism spectrum disorder in Q3 2026. Additionally, it received FDA Fast Track designation for its Alzheimer’s disease psychosis treatment and plans to advance a new M1/M4 muscarinic agonist candidate in 2026. These milestones position MapLight for significant progress in CNS disorder treatments.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
